Search Results

You are looking at 11 - 20 of 2,943 items for :

  • Refine by Access: All x
Clear All
Full access

Functional Impairment, Symptom Burden, and Clinical Outcomes Among Hospitalized Patients With Advanced Cancer

Daniel E. Lage, Areej El-Jawahri, Charn-Xin Fuh, Richard A. Newcomb, Vicki A. Jackson, David P. Ryan, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp

symptom burden and other clinical outcomes. Notably, hospitalized patients with cancer may actually experience more severe symptom burden and functional decline than those in the outpatient setting. 3 These patients are also at risk for poor clinical

Full access

Operative Techniques in Early-Stage Lung Cancer

Thomas A. D'Amico

patients. 12 , 13 Despite these outcomes, the advantages of thoracoscopic lobectomy seem to be underused. From 1999 to 2006, only 20% of all lobectomies for NSCLC were performed thoracoscopically by the board-certified thoracic surgeons participating in

Full access

Point: Fluoroquinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Cancer Patients Works for Defined Outcomes in Defined Populations, but Must Be Used Wisely

Eric J. Bow

economic outcomes of hematopoietic stem-cell transplantation . J Clin Oncol 2001 ; 19 : 2201 – 2205 . 12 Sonis ST Elting LS Keefe D . Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and

Full access

Competing Outcomes

Rodger J. Winn

. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines . J Clin Oncol 1996 ; 14 : 671 – 679 . 3 Nease RF Kneeland T O'Connor GT . Variation in patient utilities for outcomes of the management of chronic stable

Full access

Role of Radioactive Iodine for Adjuvant Therapy and Treatment of Metastases

Jacqueline Jonklaas

between effective radiation dose and outcome of radioiodine therapy for thyroid cancer . N Engl J Med 1983 ; 309 : 937 – 941 . 16. Maxon HR III Englaro EE Thomas SR . Radioiodine-131 therapy for well-differentiated thyroid cancer

Full access

Associations Between Surrogates’ Decisional Regret Trajectories and Bereavement Outcomes

Fur-Hsing Wen, Chia-Hsun Hsieh, Wen-Chi Shen, Ming-Mo Hou, Po-Jung Su, Wen-Chi Chou, Jen-Shi Chen, Wen-Cheng Chang, and Siew Tzuh Tang

, particularly for unfavorable outcomes, 19 and to avoid negative bereavement outcomes that can last several months or years. 15 , 16 Indeed, higher decisional regret is associated with worse bereavement outcomes, including increased symptoms of anxiety, 20

Full access

Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112

Tarah J. Ballinger, Helga S. Marques, Gloria Xue, Richard Hoffman, Constantine Gatsonis, Fengmin Zhao, Kathy D. Miller, Joseph Sparano, and Roisin M. Connolly

Background Observational data investigating the relationship between body habitus and outcomes in breast cancer have been largely centered in the curative setting and focused on weight-based metrics, with variable and inconsistent results

Full access

Harmonized Outcome Measures for Use in Non–Small Cell Lung Cancer Patient Registries and Clinical Practice

Martin J. Edelman, Daniel P. Raymond, Dwight H. Owen, Michelle B. Leavy, Kari Chansky, Sriram Yennu, Felix G. Fernandez, Carolyn J. Presley, Tithi Biswas, Gwendolyn P. Quinn, Matthew B. Schabath, Seth Sheffler-Collins, Laura Chu, and Richard E. Gliklich

immunotherapy with chemotherapy, and which patients are unlikely to receive clinical benefit from immunotherapy. To address these and other research questions critical to improving patient outcomes, innovative research strategies and high-quality sources of data

Full access

The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis

George Rodrigues, Himu Lukka, Padraig Warde, Michael Brundage, Luis Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, Andre-Guy Martin, Eric Vigneault, Jim Morris, Andrew Warner, Sandra Gonzalez Maldonado, Tom Pickles, and the Genitourinary Radiation Oncologists of Canada (GUROC)

pretreatment risk stratification systems have been published to support decision-making, interphysician communication, clinical trial stratification/design, and outcome reporting in nonmetastatic prostate cancer. Five unique commonly used systems (not

Full access

Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States

Christopher Nevala-Plagemann, Siddharth Iyengar, Andrew D. Trunk, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna

over the past several decades. This decrease is likely attributable to improved detection of early-stage disease through increased use of appropriate cancer screening and improvements in cytotoxic and targeted therapy. Unfortunately, outcomes for